Advertisement

Tardive Dyskinesia and Subtyping of Schizophrenia

  • Dilip V. Jeste
  • Charles A. Kaufmann
  • Richard Jed Wyatt

Abstract

The history of psychiatry, especially that of the “functional psychoses,” is replete with systems of classification proposed by “splitters” and “lumpers.” Kraepelin (1907) split manic depressive illness from dementia precox and lumped under the latter category different conditions described by Morel, Kahl-baum, and Hecker. Bleuler (1911) clearly recognized the heterogeneous nature of schizophrenia and split the syndrome into paranoid, catatonic, simple and hebephrenic subtypes. Since then a number of attempts have been made to subdivide the schizophrenic syndrome into rational subgroups. Most of the traditional classifications have been based on “naturalistic” variables such as symptomatology and course. In recent years, several investigators have suggested clinical utility and potential biological validity of subtyping disorders according to patterns of response to “extraneous” variables, such as drug treatment (Klein, 1965). Since the most effective treatment of chronic schizophrenia is neuroleptic administration, it would seem logical to attempt subdividing schizophrenic patients on the basis of their response to neuroleptic treatment. While therapeutic response to neuroleptics has been used to characterize patient subgroups (neuroleptic responders versus nonresponders), we believe that it might also be useful to subtype neuroleptic-treated chronic schizophrenic patients according to the development of tardive dyskinesia (TD). In a recent study we classified schizophrenic patients into different subgroups using a number of different dimensions (Jeste et al., 1982). This paper deals with the study using the TD dimension.

Keywords

Schizophrenic Patient Tardive Dyskinesia Brief Psychiatric Rating Scale Fusaric Acid Neuroleptic Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldessarini, R. J., and Tarsy, D., 1978, Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia, Int. Rev. Neurobiol. 21: 1–45.CrossRefGoogle Scholar
  2. Bell, R. C. H., and Smith, R. C., 1978, Tardive dyskinesia: Characterization and prevalence in a statewide system, J. Clin. Psychiatry 39: 39–47.PubMedGoogle Scholar
  3. Birket-Smith, E., and Anderson, J. V., 1973, Treatment of side effects of levodopa, Lancet 1: 431.PubMedCrossRefGoogle Scholar
  4. Bleuler, E., 1911, Dementia Praecox or the Group of Schizophrenias (J. Zinkin, translator), International University Press, New York, 1950.Google Scholar
  5. Brandon, S., McClelland, H. A., and Protheroe, C., 1971, A study of facial dyskinesia in a mental hospital population, Br. J. Psychiatry 118: 171–184.PubMedCrossRefGoogle Scholar
  6. Casey, D. E., and Hansen, T. E., 1984, Spontaneous dyskinesias, in: Neuropsychiatric Movement Disorders ( D. V. Jeste and R. J. Wyatt, eds.), pp. 68–95, American Psychiatric Press, Washington, DC.Google Scholar
  7. Crane, G. E., 1973, Clinical psychopharmacology in its 20th year, Science 181: 124–128.PubMedCrossRefGoogle Scholar
  8. DeLisi, L. E., Phelps, B. H., Wise, C. D., Apostles, P. S., Rosenblatt, J. E., Bigelow, L., and Wyatt, R. J., 1981, An effect of neuroleptic medication on plasma dopamine-p-hydroxylase activity, Biol. Psychiatry 16: 873–878.PubMedGoogle Scholar
  9. Demars, J. P. C. A., 1966, Neuromuscular effects of long-term phenothiazine medication, electroconvulsive therapy and leucotomy, J. Nerv. Ment. Dis. 143: 73–79.PubMedCrossRefGoogle Scholar
  10. Faurbye, A., Rasch, P-J., Petersen, P. B., Brandborg, G., and Pakkenberg, H., 1964, Neurological symptoms in pharmacotherapy of psychoses, Acta Psychiatr. Scand. 40: 10–27.PubMedCrossRefGoogle Scholar
  11. Gardos, G., Cole, J. O., and La Brie, R. A., 1977, Drug variables in the etiology of tardive dyskinesia: Application of discriminant function analysis, Prog. Neuropsychopharmacol. 1: 147–154.PubMedCrossRefGoogle Scholar
  12. Glassman, R. B., and Glassman, H. N., 1980, Oral dyskinesias in brain-damaged rats withdrawn from a neuroleptic: Implication for models of tardive dyskinesia Psychopharmacology 69: 19–25.PubMedCrossRefGoogle Scholar
  13. Gunne, L. M., and Growdon, J. H., 1982, A model for oral dyskinesia in rats, J. Clin. Psychopharmacol. 2: 308–311.PubMedCrossRefGoogle Scholar
  14. Heinrich, K., Wagener, I., and Bender, H-J., 1968, Spate extrapyramidal hyperkinesen bei neuroleptischer langzelttherapie, Pharmakopsychiat. Neuropsychopharmakol. 1: 169–195.CrossRefGoogle Scholar
  15. Jeste, D. V., and Wyatt, R. J., 1982, Understanding and Treating Tardive Dyskinesia, Guilford Press, New York.Google Scholar
  16. Jeste, D. V., Potkin, S. G., Sinha, S., Feder, S. L., and Wyatt, R. J., 1979, Tardive dyskinesiaReversible and persistent, Arch. Gen. Psychiatry 36: 585–590.PubMedCrossRefGoogle Scholar
  17. Jeste, D. V., Kleinman, J. E., Potkin, S. G., Luchins, D. J., and Weinberger, D. R., 1982, Ex Uno Multi: Subtyping the schizophrenic syndrome, Biol. Psychiatry 17: 199–222.PubMedGoogle Scholar
  18. Jeste, D. V., Jeste, S. D., and Wyatt, R. J., 1983, Reversible tardive dyskinesia: Implications for therapeutic strategy and prevention of tardive dyskinesia, in: New Research in Tardive Dyskinesia ( J Bannet and R. Belmaker, eds.), pp. 34–48, Plenum Press, New York.Google Scholar
  19. Jus, A., Pineau, R., Lachance, R., Pelchat, G., Jus, K., Pires, P., and Villeneuve, R., 1976, Epidemiology of tardive dyskinesia, Part II, Dis. Nerv. Syst. 37: 257–261.PubMedGoogle Scholar
  20. Kane, J. M., Woerner, M., Lieberman, J., et al.,1984, Tardive dyskinesia, in: Neuropsychiatric Movement Disorders (D. V. Jeste and R. J. Wyatt, eds.), pp. 98–118, American Psychiatric Press, Washington, DC.Google Scholar
  21. Kennedy, P. F., Hershon, H. I., and McGuire, R. J., 1971, Extrapyramidal disorders after prolonged phenothiazine therapy, Br. J. Psychiatry 118: 509–518.PubMedCrossRefGoogle Scholar
  22. Klawans, H. L., Jr., 1973, The pharmacology of tardive dyskinesia, Am. J. Psychiatry 130: 82–86.PubMedGoogle Scholar
  23. Klein, D. F., 1965, Diagnosis and pattern of reaction to drug treatment: Clinically derived for mulations, in: Classification in Psychiatry and Psychopathology ( M. M. Katz, J. O. Cole and W. E. Barton, eds.), US Government Printing Office, Washington, DC.Google Scholar
  24. Kovacic, B., and Domino, E. F., 1982, A monkey model of tardive dyskinesia (TD): Evidence that reversible TD may turn into irreversible TD, J. Clin. Psychopharmacol. 2: 305–307.PubMedCrossRefGoogle Scholar
  25. Kraepelin, E., 1907, Dementia Praecox and Paraphrenia, (R. M. Barclay, and G. M. Robertson, translators), Robert E. Krieger, New York, 1971.Google Scholar
  26. Lieberman, A. N., Freeman, L. S., and Goldstein, M., 1972, Serum dopamine-ß-hydroxylase activity in patients with Huntington’s chorea and Parkinson’s disease Lancet 1: 153–154.PubMedCrossRefGoogle Scholar
  27. Mallya, A., Jose, C., Baig, M., Williams, R., Cho, D., Mehta, D., and Volavka, J., 1979, Antiparkinsonics, neuroleptics and tardive dyskinesia, Biol. Psychiatry 14: 645–649.PubMedGoogle Scholar
  28. Meltzer, H. Y., Nasr, S. J., and Tong, C., 1980, Serum dopamine-ß-hydroxylase activity in schizophrenia, Biol. Psychiatry 15: 781.PubMedGoogle Scholar
  29. Nagatsu, T., and Udenfriend, S., 1972, Photmetric assay of dopamine-3-hydroxylase activity in human blood, Clin. Chem. 18: 980–983.PubMedGoogle Scholar
  30. National Institute of Mental Health, 1976, Abnormal involuntary movement scale, in: ECDEU Assessment Manual ( W. Guy, ed.), pp. 534–537, US Department of Health, Education and Welfare, Rockville, Maryland.Google Scholar
  31. Overall, J. E., and Gorham, D. R., 1962, The brief psychiatric rating scale, Psychol. Rep. 10: 799–812.CrossRefGoogle Scholar
  32. Pandurangi, A. K., Ananth, J., and Channabasavanna, S. M., 1978, Dyskinesia in an Indian mental hospital, Int. J. Psychiatry 20: 339–342.Google Scholar
  33. Perenyi, A., Arato, M., Bagdy, G., et al.,1981, Long-acting neuroleptics and tardive dyskinesia. Is the high activity of serum dopamine-ß-hydroxylase indicative of “individual sensitivity”? Abstracts of the III World Congress of Biological Psychiatry, Stockholm, Abstract #F368.Google Scholar
  34. Pryce, I. G., and Edwards, H., 1966, Persistent oral dyskinesia in female mental hospital patients, Br. J. Psychiatry 112: 983–987.PubMedCrossRefGoogle Scholar
  35. Simpson, G. M., Varga, E., Lee, J. H., and Zoubok, B., 1978, Tardive dyskinesia and psychotropic drug history, Psychopharmacology 58: 117–124.PubMedCrossRefGoogle Scholar
  36. Smith, J. M., Oswald, W. T., Kucharski, L. T., and Waterman, L. J., 1978, Tardive dyskinesia: Age and sex differences in hospitalized schizophrenics, Psychopharmacology 58: 207–211.PubMedCrossRefGoogle Scholar
  37. Spitzer, R. L., Endicott, J., and Robins, E., 1975, Clinical criteria for psychiatric diagnosis and DSM-II, Am. J. Psychiatry 132: 1187–1192.PubMedGoogle Scholar
  38. Viukari, M., and Linnoila, M., 1977, Effect of fusaric acid on tardive dyskinesia and mental state in psychogeriatric patients, Acta Psychiatr. Scand. 56: 57–61.PubMedCrossRefGoogle Scholar
  39. Weinberger, D. R., Torrey, E. F., Neophytides, A. N., et al., 1979, Lateral cerebral ventricular enlargement in chronic schizophrenia, Arch. Gen. Psychiatry 36:735–739.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Dilip V. Jeste
    • 1
  • Charles A. Kaufmann
    • 1
  • Richard Jed Wyatt
    • 1
  1. 1.Neuropsychiatry Branch, National Institute of Mental HealthSaint Elizabeths HospitalUSA

Personalised recommendations